Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹262 Cr revenue.
COGS 43.6%, employees 13.4%.
“Our next milestone is 4,000 crores...anywhere between two to three years is what we should write our first milestone”
“revenue grew by 10.”
“4,000 crores by next two to three years (FY28/29), then 5,000 crores milestone”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.4%▼ | 10.5% |
| ROCE | 13.1%▼ | 13.8% |
| Net Margin | 12.6%▲ | 8.7% |
| EBITDA Margin | 21.1%▲ | 16.0% |
| Debt To Equity | 0.01x▼ | 0.21x |
| Rev Growth 3yr | -44.0%▼ | 5.8% |
| EPS Growth 3yr | -43.1%▼ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,166 Cr +725.7% | ₹262 Cr -88.0% | ₹2,177 Cr +17.6% | ₹1,852 Cr +24.2% | ₹1,491 Cr +8.3% | ₹1,376 Cr +21.3% | ₹1,134 Cr +13.4% | ₹1,000 Cr |
| Other Income | ₹49 Cr +596.4% | ₹7 Cr -86.0% | ₹50 Cr -15.0% | ₹59 Cr +41.7% | ₹42 Cr +525.2% | ₹7 Cr | ₹0.33 Cr -92.9% | ₹5 Cr |
| Total Income | ₹2,215 Cr +722.3% | ₹269 Cr -87.9% | ₹2,228 Cr +16.6% | ₹1,911 Cr +24.7% | ₹1,533 Cr +10.8% | ₹1,383 Cr +21.9% | ₹1,135 Cr +12.9% | ₹1,005 Cr |
| COGS | ₹919 Cr +703.6% | ₹114 Cr -89.0% | ₹1,038 Cr +12.7% | ₹921 Cr +28.5% | ₹717 Cr +20.5% | ₹595 Cr +9.2% | ₹545 Cr +9.4% | ₹498 Cr |
| ₹1,843 Cr +741.6% | ₹219 Cr -87.9% | ₹1,804 Cr +14.6% | ₹1,574 Cr +22.5% | ₹1,285 Cr +18.9% | ₹1,081 Cr +10.6% | ₹977 Cr +8.5% | ₹900 Cr | |
| Profit Before Tax | ₹372 Cr +638.5% | ₹50 Cr -88.1% | ₹424 Cr +25.4% | ₹338 Cr +36.4% | ₹248 Cr -18.1% | ₹302 Cr +92.2% | ₹157 Cr +50.7% | ₹104 Cr |
| ₹92 Cr +658.7% | ₹12 Cr -88.8% | ₹109 Cr +50.2% | ₹72 Cr +19.2% | ₹61 Cr -4.6% | ₹64 Cr +74.7% | ₹36 Cr +52.6% | ₹24 Cr | |
| Net Profit | ₹280 Cr +632.1% | ₹38 Cr -87.8% | ₹315 Cr +18.7% | ₹265 Cr +42.0% | ₹187 Cr -21.7% | ₹239 Cr +97.5% | ₹121 Cr +50.1% | ₹80 Cr |
| Profit (Owners) | ₹279 Cr +628.8% | ₹38 Cr -87.8% | ₹314 Cr +18.3% | ₹265 Cr +42.0% | ₹187 Cr -21.7% | ₹239 Cr +97.5% | ₹121 Cr +58.8% | ₹76 Cr |
| Minority Interest | ₹1 Cr | ₹0.00 Cr -100.0% | ₹0.94 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹4 Cr |
| Other Comprehensive Income | ₹125 Cr | ₹5 Cr -83.2% | ₹29 Cr -45.2% | ₹52 Cr +3.8% | ₹50 Cr | ₹0.47 Cr -92.9% | ₹7 Cr ↑ Recovery | (₹0.40 Cr) |
| EPS | ₹6.16 | ₹0.84 | ₹6.93 | ₹5.85 | ₹4.56 | ₹5.83 | ₹2.95 | ₹1.86 |
| Diluted Shares | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Marksans Pharma Limited has informed the Exchange about Update on acquisition of QliniQ B.V.
Marksans Pharma Limited has informed the Exchange that India Ratings and Research has revised the outlook for the Company s bank loan facilities to Positive from Stable
Marksans Pharma Limited has informed the Exchange about Schedule for Virtual Investor Conference
Marksans Pharma Limited has informed the Exchange about Transcript of Investors/Analyst meet on Q4 FY 26 Audited Financial Results
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Second 100 day Campaign- "Saksham Niveshak"
Marksans Pharma Limited has informed the Exchange about Second 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"'.
Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 01, 2026, titled "Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V., Strengthening Presence in Euro...
Marksans Pharma Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Marksans Pharma Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT ₹3,000...
Marksans Pharma Limited has informed the Exchange about Investor Presentation
Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.90 per equity share.
Marksans Pharma Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026.
Marksans Pharma Limited has informed the Exchange about Schedule of conference call for analysts and investors on Wednesday, May 27, 2026 at 04:30 PM (IST) to discuss the Audited Financial Results (St...
Marksans Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regula...
Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Marksans Pharma Limited has informed the Exchange about Newspaper publication regarding opening of special window for re-lodgement of the transfer request for physical shares